Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer and MD Anderson extend KRAS cancer collaboration

Source: 
Pharmaforum
snippet: 

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.